ácido ferúlico

Ferulic Acid: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Ferulic acid is a hydroxycinnamic acid derivative and a phenolic compound. The name ferulic originates from the genus Ferula, referring to giant fennel (Ferula communis). The International Union of Pure and Applied Chemistry (IUPAC) name for ferulic acid (FA) is (E)-3-(4-hydroxy-3-methoxy-phenyl) prop-2-enoic acid. It is also widely known by its systematic chemical name 4-hydroxy-3-methoxycinnamic acid. Classified as a phenolic phytochemical, ferulic acid is an amber-colored solid.

Chemically named 4-hydroxy-3-methoxycinnamic acid (C₁₀H₁₀O₄, MW 194.184), FA exists as cis/trans isomers (pale yellow solids). In 1925, FA was chemically synthesized and structurally confirmed by spectroscopic techniques, revealing the presence of an unsaturated side chain and the existence of both cis and trans isomeric forms. The double bond present in the side chain is subjected to cis–trans isomerization, and the resonance-stabilized phenoxy radical accounts for its effective antioxidant activity.

Occurrence in Plants

Ferulic acid is a ubiquitous natural phenolic phytochemical present in seeds and leaves, both in its free form and covalently conjugated to plant cell wall polysaccharides, glycoproteins, polyamines, lignin, and hydroxy fatty acids. In plants, FA is biosynthesized from caffeic acid by the enzyme caffeate O-methyltransferase. FA, along with dihydroferulic acid, acts as a component of lignocellulose, which crosslinks lignins and polysaccharides, thereby conferring rigidity to the cell walls. It arises from metabolism of phenylalanine and tyrosine by the Shikimate pathway in plants.

Esters of ferulic acid are found in plant cell walls, covalently bonded to hemicellulose such as arabinoxylans. Salts and esters derived from ferulic acid are called ferulates.

Natural Sources

Certain types of grasses, including rice, wheat, and oats, are highly concentrated sources of FA. In cereals, ferulic acid is localized in the bran — the hard outer layer of grain. It occurs in particularly high concentrations in popcorn and bamboo shoots. Ferulic acid is also commonly found in fruits and vegetables such as tomatoes, sweet corn, and rice bran. It is an effective component of Chinese medicine herbs such as Angelica sinensis, Cimicifuga heracleifolia, and Ligusticum chuanxiong.

Ferulic acid is mainly conjugated with mono- and oligosaccharides, polyamines, lipids, and polysaccharides, and seldom occurs in a free state in plants. In wheat, phenolic compounds are mainly found in the form of insoluble bound ferulic acid and may be relevant to resistance to wheat fungal diseases.

Common Forms and Preparations

From a technological standpoint, FA is commonly obtained from cereal brans and other plant by-products through alkaline or enzymatic hydrolysis, which cleaves ester linkages to cell wall polysaccharides and releases bound ferulates for further purification. FA occurs in both free and bound forms in foods, the latter released during digestion or fermentation. As a supplement, FA is available in oral dosage forms including capsules and tablets, as well as in topical preparations such as serums and sunscreen formulations. In the cosmetic sector, FA is widely incorporated into topical antioxidant serums, often alongside vitamins C and E, because of its photoprotective and anti-aging effects.

2. Traditional and Historical Use

Traditional Chinese Medicine

Ferulic acid is an effective component of Chinese medicine herbs such as Angelica sinensis, Cimicifuga heracleifolia, and Ligusticum chuanxiong. These herbs have been employed in TCM for millennia for conditions related to blood stasis, pain, and circulatory health. Danggui Buxue Tang (DBT), a herbal decoction composing of Astragali Radix and Angelica Sinensis Radix, has been utilized for more than 800 years in China, having a known anti-oxidative property. Ferulic acid is a major active ingredient in DBT.

FA is a natural antioxidant abundantly present in Angelica sinensis, which is a traditional Chinese herb commonly used for promotion of blood production. Dozens of traditional Chinese medicine formulas have been used for promotion of hematopoiesis for centuries, with Angelica sinensis being used as a common herb in these formulas. Angelica sinensis has also been widely used as a health food or dietary supplement for women's care.

Ferulic acid is an important polyphenol found in many traditional Chinese medicines (e.g., Ligusticum chuanxiong and Radix Angelicae Sinensis) and belongs to the cinnamic acid derivatives of phenolic acids. This compound accelerates blood circulation, removes blood stasis, and has a role in regulating coagulation.

Isolation and Modern Identification

Ferulic acid was first isolated from Ferula foetida for its structure determination, and its name was based on the botanical name of the plant. In 1925, FA was chemically synthesized and structurally confirmed by spectroscopic techniques. Classical Ayurvedic texts don't name "ferulic acid" explicitly; it is a modern chemistry term. The plants that contain ferulic acid, however — rice, wheat, turmeric, and various Angelica species — have extensive traditional use predating modern chemistry by centuries.

3. Key Constituents, Related Compounds, and Mechanisms of Action

Structural Features Underlying Biological Activity

FA catalyzes the stable phenoxy radical formation upon absorption of ultraviolet light, which gives it the strength to terminate free radical chain reactions. FA acts as a potent antioxidant by scavenging free radicals and enhancing the cell stress response through the up-regulation of cytoprotective systems, e.g., heme oxygenase-1, heat shock protein 70, extracellular signal-regulated kinase 1/2, and the proto-oncogene Akt.

FA plays a vital role in providing rigidity to the cell wall and in the formation of other important organic compounds like coniferyl alcohol, vanillin, sinapic acid, diferulic acid, and curcumin.

Antioxidant Mechanisms

Ferulic acid induces the translocation of Nrf2 from the cytoplasm to the nucleus and promotes the expression of Nrf2, which activates the antioxidant response element (ARE) and increases transcription of Nrf2-regulated genes, such as HO-1. FA activates the Nrf2/HO-1 signaling, exerting protective roles in many different organs, including the lungs, kidneys, liver, and colon.

Anti-Inflammatory Mechanisms

FA exerts effects via multiple mechanisms, including the modulation of NF-κB, MAPK, and JAK/STAT pathways, and the suppression of key proinflammatory cytokines — tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 — with these mechanisms collectively attenuating inflammatory pathology. More specifically, FA can directly target TLR4 and inhibit the TLR4/NF-κB pathway, decreasing the expression of phospho-NF-κB and downstream inflammatory mediators. Moreover, FA inhibits the expression of MAPK signaling pathway-related proteins.

FA effectively modulates multiple inflammation-associated signaling pathways, including NF-κB, MAPK, NOD-like receptor protein 3 (NLRP3), JAK/STAT, peroxisome proliferator-activated receptor gamma (PPARγ), and AMP-activated protein kinase (AMPK) cascades. These pathways operate both independently and through crosstalk mediated by reactive oxygen species (ROS) and inflammatory cytokines, collectively constituting an intricate anti-inflammatory regulatory network.

Anti-Platelet and Anticoagulant Mechanisms

In vitro assays showed inhibitory effects of ferulic acid on thrombin- or collagen/epinephrine-stimulated platelet activation by inhibiting platelet aggregation and decreasing clot retraction activity. The in vitro effect of ferulic acid on thrombin-stimulated platelet activation was proved by the decrease in the secretion of serotonin from the platelets. The anticoagulant effects of ferulic acid were confirmed by the prolongation of the intrinsic or/and extrinsic pathways and the delay of recalcification time in plasma coagulation.

Neuroprotective Mechanisms

The neuroprotective potential of FA may be due to its ability to absorb active forms of oxygen and nitrogen and to use redox-bearing compounds to regulate genetic expression, including genes encoding antioxidant enzymes, the anti-apoptotic protein family Bcl-2, and pro-survival neurotrophic factors like BDNF. Its higher bioavailability and lipophilic nature make it a better drug candidate than other polyphenols for neurological disorders.

4. Pharmacokinetics and Bioavailability

Ferulic acid is a major metabolite of chlorogenic acids in humans along with caffeic and isoferulic acid, and is absorbed in the small intestine, whereas other metabolites such as dihydroferulic acid and feruloylglycine are produced from chlorogenic acid in the large intestine by the action of gut flora.

A central theme emerging from the literature is that FA is primarily absorbed in the stomach, followed by extensive metabolic transformations in the liver via glucuronidation, sulfation, and hydroxylation. Individual variations in age, gender, race, and gut microbiota can significantly impact metabolic regulation and FA bioavailability.

Studies in humans show that the peak time for maximal urinary excretion is approximately 7 hours and the recovery of ferulic acid in urine, on the basis of total free ferulic acid and feruloyl glucuronide excreted, is 11–25% of that ingested. Several studies have reported highly variable results on FA bioavailability (0.4–98%). The binding of FA to polysaccharides may limit its bioavailability. Studies show low bioaccessibility of FA from wheat fractions and breads (<1%). However, the bioaccessibility was high when free FA was added to flour (approximately 60%).

FA exhibits therapeutic potential for various disorders, but its clinical application is hindered by poor bioavailability and solubility. Efforts to address this limitation include the use of lipid nanoparticle delivery systems; FA-loaded lipid nanoparticles enhanced FA's bioavailability without apparent systemic toxicity or neurotoxicity, though longer treatment durations may be necessary to observe potential neuroprotective benefits and toxicity.

5. Scientific Evidence by Area of Use

5.1 Antioxidant Activity

FA exhibits a wide range of therapeutic effects against various diseases like cancer, diabetes, cardiovascular, and neurodegenerative diseases. A wide spectrum of beneficial activity for human health has been advocated for this phenolic compound, at least in part, because of its strong antioxidant activity. The antioxidant mechanisms are well-established at the molecular level. The antioxidant effect of FA has been verified against several acute and chronic pathologies such as intestinal ischemia, cancer, cardiovascular and skin diseases, diabetes, cochlear oxidative damage due to repeated noise exposure, and oxidative cellular stress in human dermal fibroblasts. The great majority of this evidence, however, is from in vitro and animal studies; large, controlled human trials specifically measuring FA antioxidant outcomes in isolation remain limited.

5.2 Neurological Health — Alzheimer's Disease and Cognitive Decline

Among polyphenols, ferulic acid is a hydroxycinnamic acid derivative, widely distributed in nature, especially in cereal bran and fruits, and known to be endowed with many bioactivities, especially antioxidant, anti-inflammatory, and antidiabetic, thus suggesting it could be exploited as a possible novel neuroprotective strategy.

Preclinical evidence: Many preclinical studies show that ferulic acid displays neuroprotective effects in Alzheimer's disease (AD) models. A systematic review and meta-analysis of published preclinical research included a total of 344 animals across 12 papers. Results show that FA treatment can effectively improve rodents' spatial memory ability in Morris Water Maze and Y maze experiments, and reduce the deposition of amyloid beta (Aβ) in the brains of various model animals.

Human/Clinical evidence: In one randomized controlled trial, participants aged 65 to 85 years old with mild cognitive impairment (MCI) were randomly allocated to an active group (n = 30), receiving a Feru-guard® daily dose equal to 200 mg of ferulic acid and 40 mg of Angelica archangelica extract, or to a placebo group (n = 26). Participants took the supplement or placebo before breakfast and dinner every day throughout the 48-week trial period. In the intention-to-treat population, Mini-Mental State Examination (MMSE) scores were significantly better at 24 weeks in the active group, and in the per-protocol population, significant differences were also seen for the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Japanese version (ADAS-Jcog) at 24 and 48 weeks. It should be noted that this trial used a combination product (ferulic acid plus Angelica extract), making it difficult to attribute effects to ferulic acid alone.

In summary, current research on FA and AD is still at the basic research stage. No dedicated clinical trial for isolated ferulic acid in AD has been registered on ClinicalTrials.gov (as of mid-2021). The evidence base for ferulic acid in human neurodegenerative conditions is therefore considered preliminary.

In terms of mechanism relevant to Alzheimer's disease specifically, text mining and in vitro data identified BACE1 and MMP2 as being implicated in the activity of FA in AD. Exposure of SHSY5Y-APP cells to FA resulted in a decrease in expression levels of BACE-1 and APP, while the expression of MMP-2 and MMP-9 increased in a dose-dependent manner, suggesting that FA-induced BACE1 and MMP2 pathways may be novel potential mechanisms involved in AD.

5.3 Neuroprotection Against Ischemic Injury

Preclinical evidence: One study investigated the potential neuroprotective effects of FA against ischemia/reperfusion (I/R)-induced brain injury in vivo and in vitro using hematoxylin and eosin staining, flow cytometry, and western blot analysis. Models of cerebral I/R injury were established using rats and pheochromocytoma cells. The results revealed that treatment with FA significantly attenuated memory impairment and reduced hippocampal neuronal apoptosis and oxidative stress in a dose-dependent manner. FA attenuated memory dysfunction and exerted protective effects against oxidative stress and apoptosis induced by I/R injury by inhibiting the TLR4/MyD88 signaling pathway. These findings are from animal models; no dedicated human clinical trials of FA for ischemia have been published.

5.4 Cardiovascular Health

Ferulic acid has been reported to have many physiological functions, including antioxidant, antimicrobial, anti-inflammatory, anti-thrombosis, and anti-cancer activities. It also protects against coronary disease and lowers cholesterol.

Studies have shown that ferulic acid exerts antithrombotic effects by inhibiting platelet aggregation and protecting endothelial cells. At the same time, ferulic acid promotes the formation and differentiation of hematopoietic progenitor cells, protects intestinal cells from damage, and has fewer side effects on platelets, leukocytes, and the gastrointestinal tract, making it a potential protectant against thrombotic diseases, such as cardiovascular dysfunction, pulmonary thromboembolism, and deep vein thrombosis.

Ferulic acid has been found to attenuate isoprenaline-induced mouse heart fibrosis and cell apoptosis by reducing oxidative stress, inflammation, and apoptosis in vivo, providing insight into the clinical application of ferulic acid in the treatment of cardiovascular diseases. These findings are from animal models. The cardiovascular evidence base in humans is largely epidemiological (linking whole-grain and polyphenol-rich diets to cardiovascular benefit) rather than from isolated ferulic acid trials.

5.5 Metabolic Health — Diabetes and Metabolic Syndrome

Numerous in vitro and in vivo studies demonstrate antioxidant, anti-inflammatory, antidiabetic, cardioprotective, and neuroprotective effects of FA, positioning it as a promising nutraceutical for managing chronic diseases, particularly metabolic syndrome (MetS), a cluster of conditions (obesity, insulin resistance, hypertension, dyslipidemia) that elevate the risk of type 2 diabetes and cardiovascular disease.

FA has shown preventive and therapeutic potential in managing metabolic syndrome by improving glucose and lipid metabolism, lowering blood pressure, reducing oxidative stress, and modulating inflammatory and microbiota-related pathways.

At the molecular level in cell studies, insulin receptor substrate 1 (IRS1)/PI3K/AKT/GSK3-β is the most important signaling pathway for regulating blood glucose levels. At the cellular level, FA increased the survival rate of palmitate-treated cells and inhibited apoptosis and reduced oxidative stress through this pathway. In addition, FA reversed the low expression of Nrf2 and Gpx4 proteins in mice caused by high-fat diets.

Limitations of human evidence: Existing trials did not report any adverse glycemic effects, indicating that FA can be safely used as a nutraceutical adjunct, but they also suggest that ferulic acid alone may not dramatically lower blood glucose or HbA1c in the short term in humans. To date, no large-scale clinical trial has specifically evaluated isolated ferulic acid for glycemic control in diabetic patients; thus, the efficacy of FA in lowering HbA1c or improving insulin resistance in humans remains an open question.

5.6 Cancer — Preclinical Evidence

Ferulic acid, a natural compound derived from various seeds, nuts, leaves, and fruits, exhibits a variety of pharmacological effects in cancer, including proapoptotic, cell-cycle-arresting, anti-metastatic, and anti-inflammatory activities. Reviews present a thorough overview of the molecular targets and cellular signaling pathways modulated by ferulic acid in diverse malignancies, showing high potential for this phenolic acid to be developed as a candidate agent for novel anticancer therapeutics.

At the cellular level, treating Caco-2 colorectal cells at a concentration of 1500 μM markedly enhanced the length of the S phase and cell cycle arrest. In cervical carcinoma cell lines (Hela and CaSki), FA at concentrations from 4 μM led to cell cycle arrest in the G0/G1 phase by reducing cell invasion and cyclin D1 and cyclin E levels. A ferulic acid derivative tested on HCT116, HT-29, and Caco-2 colon cancer cells at 40 μM stopped the G0/G1 phase, leading to cytotoxicity and cell death.

The findings of preclinical research suggest that FA demonstrates promising anticancer effects in preclinical pharmacological test methods. No clinical (human) trials of ferulic acid as a standalone anticancer agent have been published; all cancer evidence is from in vitro cell studies or animal models, and should be interpreted as hypothesis-generating only.

5.7 Skin Health — Topical and Photoprotective Use

This is one of the areas with the strongest evidence specifically from studies involving human skin. One well-cited human study sought to determine whether a stable topical formulation of 15% L-ascorbic acid, 1% alpha-tocopherol, and 0.5% ferulic acid (CEFer) could protect human skin in vivo from solar-simulated UV radiation. The formulation and its vehicle were applied to separate patches of normal-appearing human skin for 4 days, then irradiated with solar-simulated UV at 2 to 10 minimal erythema doses. Skin was evaluated for erythema, sunburn cells, thymine dimers, p53, and UV-induced cytokines. CEFer provided significant and meaningful photoprotection for skin by all methods of evaluation; however, the number of patients evaluated was relatively small.

The addition of ferulic acid in sunscreens can improve their sun protection factor (SPF) and prevent inflammatory reactions. In clinical assessments, samples had good skin biocompatibility and presented satisfactory safety profiles, even in sun-exposed conditions. A synergic effect between the natural polyphenol and UV filters was evidenced; FA increased in vivo SPF in 37% and the UVA protection factor (UVA-PF) in 26%. The in vivo data indicated that FA reinforced the broad-spectrum characteristic of the photoprotective formulations.

Ferulic acid was found to regulate antioxidation, senescence, and DNA damage mechanisms through Gadd45α signaling pathways. Ferulic acid downregulates MMP1 and MMP3 gene expression, thereby demonstrating protective effects on the dermis layer through ECM reconstruction. These findings indicate that ferulic acid can reverse the effects of aging in the skin by modulating its physiological structure.

Studies have evaluated FA's effect on skin erythema, pigmentation, hydration, elasticity, and texture. While the existing literature supports the photoprotective and anti-aging effects of topical FA, larger-scale and more targeted studies are needed. Daily use of topical 0.5 to 1% FA for at least 1 to 3 months appears to achieve therapeutic benefits, such as improved skin erythema, hyperpigmentation, hydration, elasticity, texture, and density.

5.8 Pulmonary Health

Accumulating evidence suggests that FA improves lung function and survival in pulmonary diseases, including idiopathic pulmonary fibrosis (IPF), acute lung injury/acute respiratory distress syndrome (ALI/ARDS), and lung cancer. However, low bioavailability and the limited number of clinical studies have restricted the use of FA in medicine.

The pulmonary evidence is entirely preclinical. FA can directly target TLR4 and inhibit the TLR4/NF-κB pathway, decreasing the expression of phospho-NF-κB and downstream inflammatory mediators, suggesting possible therapeutic relevance to inflammatory lung conditions that warrants human investigation.

5.9 Hematopoiesis

FA, a natural antioxidant abundantly present in Angelica sinensis, directly promotes hematopoietic stem cell (HSC) maintenance and thereby boosts hematopoiesis at homeostasis. Using a mouse model of acute myelosuppressive injury induced by ionizing radiation, FA supplementation effectively safeguarded HSC maintenance and accelerated hematopoietic regeneration after acute myelosuppressive injury. Mechanistically, FA diminishes ferroptosis susceptibility of HSCs through limiting the labile iron pool, thus favoring HSC maintenance. This evidence is from animal models only.

6. Body Systems Associated with Ferulic Acid

• Central nervous system: Neuroprotective effects against oxidative stress, amyloid-beta accumulation, ischemia-reperfusion injury; emerging interest in Alzheimer's and Parkinson's disease models.
• Cardiovascular system: Antithrombotic, antiplatelet, cardioprotective, and anti-atherogenic effects documented in preclinical models.
• Metabolic system: Antidiabetic, lipid-lowering, and antihypertensive effects observed in animal studies; limited human data.
• Integumentary system (skin): Photoprotection, anti-aging, anti-pigmentation; among the best-evidenced clinical applications.
• Pulmonary system: Anti-inflammatory effects in lung injury models.
• Hematopoietic system: Promotion of stem cell maintenance and blood production in animal models.
• Hepatic system: FA can reduce oxidative stress, inflammation, and cell death by activating Nrf2/HO-1 signalling and PPAR-γ, preventing hepatotoxicity.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported exactly as they appear in the cited scientific literature. They represent investigational doses, not recommendations.

• Oral supplementation (MCI/cognitive health, human RCT): A daily dose equal to 200 mg of ferulic acid (as part of Feru-guard®, combined with 40 mg of Angelica archangelica extract), taken before breakfast and dinner every day throughout a 48-week trial period.
• Topical (skin/photoprotection, human studies): A formulation of 15% L-ascorbic acid, 1% alpha-tocopherol, and 0.5% ferulic acid applied topically for 4 days.
• Topical (dermatology, general clinical evidence): Daily use of topical 0.5 to 1% FA for at least 1 to 3 months appears to achieve therapeutic benefits.
• In vitro cell studies (cancer): Concentrations of 4 μM to 1500 μM have been used in cancer cell line studies, with effects varying by cell line and endpoint. These concentrations are not translatable to human supplementation doses.
• Animal dietary supplementation (poultry): Adding 0.1%, 0.2%, or 0.3% ferulic acid preparations to the feed of chicks increased average daily weight gain and modulated gut microbiota.

No standardized, widely accepted oral therapeutic dose has been established for humans in peer-reviewed clinical guidelines as of the current literature.

8. Safety Considerations and Interactions

General Safety Profile

Ferulic acid is a phenolic acid of low toxicity; it can be absorbed and easily metabolized in the human body. In vitro cytotoxicity assays showed that ferulic acid at approximately 300 μg/mL did not cause any significant toxicity on three cell types: platelets, leukocytes, and erythrocytes. Studies on nanoparticle-delivered FA found enhanced bioavailability without apparent systemic toxicity or neurotoxicity, though longer treatment durations may be necessary to observe potential toxicity signals.

Anticoagulant Interaction

One of the most clinically important safety signals relates to ferulic acid's antiplatelet properties and the potential for interaction with anticoagulant drugs. Dong quai (Angelica sinensis), containing ferulic acid, enhances warfarin's anticoagulant effect, increasing bleeding risk. Specifically, ferulic acid in angelica administered in vivo or in vitro inhibits platelet activating factor (PAF), inhibits platelet aggregation reaction, and enhances the anticoagulant effect of warfarin.

The mechanistic basis is well-documented: in vitro assays showed inhibitory effects of ferulic acid on thrombin- or collagen/epinephrine-stimulated platelet activation by inhibiting platelet aggregation and decreasing clot retraction activity. The anticoagulant effects of ferulic acid were confirmed by the prolongation of the intrinsic or/and extrinsic pathways and the delay of recalcification time in plasma coagulation.

In mouse studies, oral administration of FA prevented death caused by pulmonary thrombosis and prolonged the tail bleeding and clotting time, while it did not alter standard coagulation parameters, including the activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT). These findings are from animal experiments; the clinical significance in humans co-administered with anticoagulants has not been fully characterized in clinical trials, but represents a plausible concern given the pharmacological overlap.

Bioavailability and Matrix Effects

Studies have reported highly variable results on FA bioavailability (0.4–98%). The binding of FA to polysaccharides may limit its bioavailability from food sources. This variability means that the effective dose from food differs substantially from that of isolated supplements, and users should not assume equivalence between dietary ferulic acid and purified supplemental forms.

Topical Safety

Clinical assessments of ferulic acid in topical sunscreen formulations demonstrated that samples had good skin biocompatibility and presented satisfactory safety profiles, even in sun-exposed conditions. Its inclusion in cosmetic formulations demonstrates synergistic photoprotective effects with conventional UV filters and antioxidant support for vitamins C and E, although formulation challenges remain.

Evidence Gaps and Overall Strength Assessment

The overall strength of evidence for ferulic acid in human health is preliminary to moderate, with the exception of topical photoprotection, which has moderate-quality human evidence. The large majority of mechanistic and efficacy data derives from in vitro cell studies and animal models. Very few randomized controlled trials in humans have tested isolated ferulic acid, and those that exist use combination products with confounding co-ingredients. Low bioavailability and the limited number of clinical studies have restricted the use of FA in medicine. Larger, well-controlled human trials are needed across virtually all proposed therapeutic indications.

References

• Maruyama et al. (2019). A recent overview on the biological and pharmacological activities of ferulic acid. PMC / Antioxidants.
• Kumar N, Pruthi V. (2014). Potential applications of ferulic acid from natural sources. Biotechnology Reports (PMC).
• Srinivasan M et al. (2007). Ferulic acid: therapeutic potential through its antioxidant property. PubMed / Journal of Clinical Biochemistry and Nutrition.
• Mancuso C, Santangelo R. (2014). Ferulic acid: pharmacological and toxicological aspects. PubMed / Food and Chemical Toxicology.
• Topakas E et al. (2004). Ferulic acid: an antioxidant found naturally in plant cell walls and feruloyl esterases. PubMed.
• Ou S, Kwok K-C. (2004). Ferulic acid: pharmaceutical functions, preparation and applications in foods. Journal of the Science of Food and Agriculture.
• Zhang et al. (2023). Ferulic Acid: A Review of Pharmacology, Toxicology, and Therapeutic Effects on Pulmonary Diseases. PMC.
• Liu et al. (2024). The Antioxidant Properties, Metabolism, Application and Mechanism of Ferulic Acid in Medicine, Food, Cosmetics, Livestock and Poultry. PMC.
• Ferulic Acid as an Anti-Inflammatory Agent: Insights into Molecular Mechanisms, Pharmacokinetics and Applications. PMC (2025).
• Morroni G et al. (2022). Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review. PMC.
• Zheng Y et al. (2021). Ferulic Acid in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies. PMC.
• Meng X et al. (2018). Application of Ferulic Acid for Alzheimer's Disease: Combination of Text Mining and Experimental Validation. PMC / Frontiers in Neuroinformatics.
• Mani V et al. (2022). Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling. PMC.
• Ferulic acid as a promising candidate for developing selective and effective anti-cancer therapies. PMC (2025).
• Zhao Z et al. (2017). Ferulic acid exerts neuroprotective effects against cerebral ischemia/reperfusion-induced injury. PMC.
• Yeung AWK et al. (2016). Ferulic Acid Orchestrates Anti-Oxidative Properties of Danggui Buxue Tang. PLOS ONE.
• Ferulic Acid Promotes Hematopoietic Stem Cell Maintenance in Homeostasis and Injury. PMC (2025).
• Kim KC et al. (2016). Pretreatment of Ferulic Acid Protects Human Dermal Fibroblasts against Ultraviolet A Irradiation. PMC.
• Sauce R et al. (2019). Ferulic acid photoprotective properties in association with UV filters. ScienceDirect / International Journal of Pharmaceutics.
• Lin FH et al. (2008). A topical antioxidant solution containing vitamins C and E stabilized by ferulic acid provides protection for human skin against UV irradiation. ScienceDirect / Journal of the American Academy of Dermatology.
• Ferulic Acid Use for Skin Applications: A Systematic Review. Journal of Clinical and Aesthetic Dermatology (2025).
• Ferulic Acid: Mechanistic Insights and Multifaceted Applications in Metabolic Syndrome, Food Preservation, and Cosmetics. PMC (2025).
• Nardini M et al. (1998). Bioavailability of ferulic acid. PubMed / Free Radical Biology and Medicine.
• Adam A et al. (2002). The bioavailability of ferulic acid is governed primarily by the food matrix rather than its metabolism in intestine and liver in rats. PubMed.
• Safety Profile of Intravenous Ferulic Acid Nanoparticles: Acute Toxicity and Neurological Effects in Sprague-Dawley Rats. PMC (2025).
• Chen W et al. (2018). In vitro and in vivo antithrombotic and cytotoxicity effects of ferulic acid. PubMed.
• Lin CC et al. (2016). Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling. ScienceDirect / Life Sciences.
• Interaction Between Chinese Medicine and Warfarin: Clinical and Research Update. PMC / Frontiers in Pharmacology (2021).
• Risks of Oral Anticoagulants: Interactions with Drugs and Medicinal Plants. MDPI Pharmaceuticals (2025).
• Molecular mechanism and research progress on pharmacology of ferulic acid in liver diseases. Frontiers in Pharmacology (2023).
• Sgarbossa A et al. (2015). Ferulic Acid: A Hope for Alzheimer's Disease Therapy from Plants. PMC / Nutrients.